LydiaRx
Flagship programme

Pakistan National Genome Programme

A proposed one-million-genome programme for the world's fifth most populous country. Delivered in-country. Owned by the State and its citizens. Governed by Pakistanis. Built to be the reference standard for how a sovereign genome programme is run.

Why Pakistan

Scientifically irreplaceable, and nearly absent from the record.

Pakistan has more than 240 million people and one of the highest rates of consanguinity in the world. Yet it is close to absent from global genomic datasets. Few populations of this size combine a high frequency of recessive disease genes with naturally occurring human knockouts. These are the variants that show whether a drug target is safe to inhibit. A Pakistan National Genome Programme is not a regional study. It is a missing foundation of human genetics.

Where it stands

A 400-genome long-read pilot and the first Pakistani pangenome, sequenced entirely in Pakistan. 12–15 Pakistani scientists trained and certified. A laboratory and secure data environment that remain a national asset. All designed to lead into a one-million-genome national programme. The programme was submitted to the Government of Pakistan as an unsolicited proposal under its Public Procurement Rules. Discussions are advanced. The technical team is mobilised and ready to deploy.

How it's structured

Three decisions shape how it runs.

01

Scale

One million whole genomes, proposed across four phases over roughly seven years. Sequenced with long-read technology at 30× coverage. A T2T Pakistani pangenome (a population-specific reference built from the cohort's own haplotypes) replaces a European-anchored reference that mismaps South Asian variation.

02

Route

Submitted as an unsolicited proposal under Pakistan's Public Procurement Rules: a privately financed programme with no call on the public purse, brought under a lawful procurement route.

03

Model

The State owns the data. A national laboratory network operates collection and sequencing through a locally majority-owned joint venture. LydiaRx supplies the sovereign platform, analytics, supply chain and governance design. No sample and no raw genomic data leaves Pakistan.

Demonstration pilot

The reference standard for everything that follows.

The pilot sequences 400 whole genomes at 30× long-read coverage over six to nine months. It builds the first Pakistani T2T pangenome from them. It is sized to prove the platform, the consent model and the reference method before scale. Consent is tiered and runs in Urdu and regional languages. A Pakistani-majority Data Access Committee decides every use of the data. Ethics approval comes before the first participant is approached. Independent audits are published at months three and nine. The pangenome is released open-access from Pakistani soil. No output is commercialised before the government agreement is signed. Every discovery from the pilot is royalty-free to Pakistan's health system.

The platform on the ground

Atlas, Phylax and Prism. In Pakistan, Phylax is Pasban.

Analysis comes to the data. The data never leaves. Atlas holds raw signal, alignments and variants on in-country infrastructure. It answers each approved question inside the environment. Phylax admits each analysis only against purpose, consent and entitlement. It meters what leaves and writes every action to a ledger the State can verify. Prism keeps every report consistent with one versioned body of evidence.

INSIDE THE COUNTRY · STATE-CONTROLLED INFRASTRUCTURE Samples · rawdata NEVER LEAVE Biobank, raw signaland genomes ownedby the State, heldunder the Charter in apublic institution Atlas ANALYSIS COMES IN Governed retrievalplan; computation onthe data; provenanceledger Phylax GUARDS THE EXIT Consent, purpose,budget; disclosurecontrol; model test;verifiable ledger Research partners ANSWERS, NOT DATA Governed, non-identifyingresults with a provenancecertificate; access fees androyalties paid questions in answers out · no copies Every item of data carries a provenance ledger. A partner's question is answered by agoverned retrieval plan executed inside the environment; only the result leaves, afterautomatic disclosure control. Analysis comes to the data. The data never goes anywhere.
Roles and governance

Who does what.

  • Ownership of raw genomic data

    The State and its citizens. LydiaRx acts as authorised custodian.

  • Government counterparty

    The Government of Pakistan.

  • Operational partner

    Collection, biobanking and sequencing, run through a national laboratory network via a locally majority-owned joint venture.

  • Technical and structuring partner

    LydiaRx: the sovereign platform, analytics, supply chain, financing structure and governance design.

  • Independent oversight

    A Governance and Ethics Board with Pakistan-resident clinical and academic co-leads, and a Pakistani-majority Data Access Committee that decides every use of the data.

Proof, not ceiling

Pakistan is the foundation programme, not the limit. Every element is designed for reuse: the custody architecture, the consent model, the oversight structure and the licensing model for governed outputs. Any nation that wants its genome to be its own asset can use them.

Ready to build your country's genome programme?

Start with a briefing. It commits you to nothing.